The stock price of Q32 Bio Inc. is primarily driven by clinical trial milestones, regulatory updates from health authorities such as the Food and Drug Administration, and pipeline advancement announcements. Because it is a clinical-stage biopharmaceutical firm without commercial product sales, investor sentiment is highly sensitive to data readouts from mid-stage trials. Furthermore, capital-raising activities like secondary public offerings, private placements, and broader macroeconomic shifts in investor appetite toward speculative biotech equities heavily influence its trading valuation.